Photo of Kevin Winthrop, M.D., M.P.H.

Kevin Winthrop M.D., M.P.H.

Dr. Winthrop specializes in international ophthalmology, public health and infectious disease epidemiology with an emphasis in mycobacterial diseases and opportunistic infections associated with rheumatic disease and immunosuppressive therapies. He has a special focus in:

  • Chronic chest infections of all etiology, including mycobacteria
  • The prevention and treatment of infections associated with Biologics and other Immunosuppressive therapies
  • Tuberculosis of the eye (Ophthalmology)
Read more

Education

  • M.D., Oregon Health & Science University, Portland Oregon 2005
  • M.P.H., Univerisity of California at Berkeley, Berkeley California 2010
  • Residency:

    • Stanford University
  • Fellowship:

    • National Jewish Medical Center, Denver, Colorado

Publications

  • "The emerging safety profile of JAK inhibitors in rheumatic disease." Nature Reviews Rheumatology In: , Vol. 13, No. 4, 01.04.2017, p. 234-243.
  • "Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease." American Journal of Respiratory and Critical Care Medicine In: , Vol. 195, No. 6, 15.03.2017, p. 814-823.
  • "Pulmonary nontuberculous mycobacteria-associated deaths, Ontario, Canada, 2001-2013." Emerging Infectious Diseases In: , Vol. 23, No. 3, 01.03.2017, p. 468-476.
  • "Disseminated nontuberculous mycobacteria in HIV-infected patients, Oregon, USA, 2007–2012." Emerging Infectious Diseases In: , Vol. 23, No. 3, 01.03.2017, p. 533-535.
  • "On the reportability of nontuberculous mycobacterial disease to public health authorities." Annals of the American Thoracic Society  In: , Vol. 14, No. 3, 01.03.2017, p. 314-317.
  • "Infection and Malignancy in Rheumatic Diseases." Rheumatic Disease Clinics of North America In: , Vol. 43, No. 1, 01.02.2017, p. xiii-xiv.
  • "Vaccines and Disease-Modifying Antirheumatic Drugs : Practical Implications for the Rheumatologist." Rheumatic Disease Clinics of North America In: , Vol. 43, No. 1, 01.02.2017, p. 1-13.
  • "Herpes Zoster and the Risk of Stroke in Patients With Autoimmune Diseases." Arthritis and Rheumatology In: , Vol. 69, No. 2, 01.02.2017, p. 439-446.
  • "Pathogens and antibiotic sensitivities in endophthalmitis." Clinical and Experimental Ophthalmology In: , 2017.
  • "Treatments for lupus nephritis : A systematic review and network metaanalysis." Journal of Rheumatology In: , Vol. 43, No. 10, 01.10.2016, p. 1801-1815.
  • "Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases : Implications for Vaccination." Arthritis and Rheumatology In: , Vol. 68, No. 9, 01.09.2016, p. 2328-2337.
  • "Patient-centered research priorities for pulmonary nontuberculous mycobacteria (NTM) infection an NTM research consortium workshop report." Annals of the American Thoracic Society In: , Vol. 13, No. 9, 01.09.2016, p. S379-S384.
  • "Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis." Annals of the Rheumatic Diseases In: , 29.07.2016.
  • "Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis." Annals of the Rheumatic Diseases In: , 25.04.2016.
  • "Influenza and pneumococcal vaccination uptake in patients with rheumatoid arthritis treated with immunosuppressive therapy in the UK : A retrospective cohort study using data from the clinical practice research datalink." PLoS One In: , Vol. 11, No. 4, e0153848, 01.04.2016.
  • "Vaccinations for rheumatoid arthritis." Current Opinion in Rheumatology  In: , 16.03.2016.
  • "Treatment of mycobacterium abscessus infection." Emerging Infectious Diseases In: , Vol. 22, No. 3, 01.03.2016, p. 511-514.
  • "Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations : Viewpoints from an EULAR task force." Annals of the Rheumatic Diseases  In: , 01.03.2016.
  • "A rhesus macaque model of pulmonary nontuberculous mycobacterial disease." American Journal of Respiratory Cell and Molecular Biology  In: , Vol. 54, No. 2, 01.02.2016, p. 170-176.
  • "Comparative Risk of Hospitalized Infection Associated with Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare." Arthritis and Rheumatology In: , Vol. 68, No. 1, 01.01.2016, p. 56-66.
  • "US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis : Executive summary." Thorax In: , Vol. 71, No. 1, 01.01.2016, p. 88-90.
  • "Diabetes as an increasingly common comorbidity among patient hospitalizations for tuberculosis in the USA." BMJ Open Diabetes Research and Care In: , Vol. 4, No. 1, e000268, 01.01.2016.
  • "US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis." Thorax  In: , Vol. 71, 01.01.2016, p. i1-i22.
  • "Infection Risk and Safety of Corticosteroid Use." Rheumatic Disease Clinics of North America In: , Vol. 42, No. 1, 2016, p. 157-176.
  • "The unmet need in rheumatology : Reports from the Targeted Therapies meeting 2016." Clinical and Experimental Rheumatology In: , Vol. 34, 2016, p. 69-76.
  • "Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases : Consensus recommendations for infection reporting during clinical trials and postmarketing surveillance." Annals of the Rheumatic Diseases In: , Vol. 74, No. 12, 01.12.2015, p. 2107-2116.
  • "BAFF inhibition does not significantly impair immunization responses in patients with rheumatoid arthritis." Arthritis Research and Therapy In: , Vol. 17, No. 1, 347, 30.11.2015.
  • "Reply to : Comment on 'Time to update guidelines on screening for latent tuberculosis infection in dermatologic patients being treated with tumor necrosis factor-alfa inhibitors'." Journal of the American Academy of Dermatology In: , Vol. 73, No. 3, 01.09.2015, p. e125-e126.
  • "Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis." Annals of the Rheumatic Diseases In: , 28.08.2015.
  • "Reply." Arthritis Care and Research  In: , Vol. 67, No. 7, 01.07.2015, p. 1041-1042.

Additional information

Edit profile